SSTR2 and hereditary pheochromocytoma-paraganglioma: This preclinical study, conducted in an SSTR2-positive mouse pheochromocytoma model, demonstrates efficacy of targeted somatostatin receptor radionuclide therapies with [67Cu]Cu‐NODAGA-TATE and [67Cu]Cu‐NODAGA-cLAB4‐TATE.